Skip to main content
Log in

The Francis Crick Institute: Scientific Discovery Open to Translation

  • Current Opinion
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

The UK is rich in discovery science, but not enough of this world-leading science is translated for health and wealth benefits. Over the past several years, strategies have been launched in both the academic and industrial sectors to improve these outcomes. However, in order to make a step change, academia and industry need to collaborate better and in new ways. This article describes the translation strategy for the Francis Crick Institute.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Department for Business, Innovation & Skills. Performance of the UK research base: international comparison—2013. https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013. Accessed 29 Feb 2016.

  2. House of Commons Science and Technology Select Committee. Science and Technology Committee—eighth report. Bridging the valley of death: improving the commercialisation of research. http://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/348/34802.htm. Accessed 29 Feb 2016.

  3. The Francis Crick Institute. Discovery without boundaries: strategy 2013. http://www.crick.ac.uk/strategy. Accessed 29 Feb 2016.

  4. NESTA. All together now: improving cross-sector collaboration in the UK biomedical industry. http://www.nesta.org.uk/publications/all-together-now-improving-cross-sector-collaboration-uk-biomedical-industry. Accessed 29 Feb 2016.

  5. Sharp PA. Meeting global challenges: discovery and innovation through convergence. Science. 2014;346(6216):1468–71.

    Article  CAS  Google Scholar 

  6. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med. 2003;114(6):477–84.

    Article  PubMed  Google Scholar 

  7. Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, Macleod MR. Can animal models of disease reliably inform human studies? PLOS Med. 2010;7:e1000245.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6:114–8.

    PubMed  PubMed Central  Google Scholar 

  9. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13:419–31.

    Article  CAS  PubMed  Google Scholar 

  10. Crick F, Koch C. The problem of consciousness. Sci Am. 1992;267(3):152–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Roblin.

Ethics declarations

Funding

None.

Conflict of interest

David Roblin is the Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute in London. He previously practised medicine in the UK, followed by a career in the biotech and pharmaceutical industry, where he became Head of Pfizer’s R&D in Europe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roblin, D. The Francis Crick Institute: Scientific Discovery Open to Translation. Pharm Med 30, 133–135 (2016). https://doi.org/10.1007/s40290-016-0143-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-016-0143-9

Keywords

Navigation